<DOC>
	<DOCNO>NCT01279590</DOCNO>
	<brief_summary>The purpose study assess incidence statin-associated myalgia ( SAM ) treatment PPD10558 versus atorvastatin patient previously intolerant statin . To assess safety tolerability PPD10558 compare atorvastatin patient previously intolerant statin .</brief_summary>
	<brief_title>Study Safety Tolerability Associated With PPD10558 Versus Atorvastatin Patients Previously Intolerant Statins Due Statin-associated Myalgia ( SAM )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Myalgia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>diagnosis primary hypercholesterolemia ( heterozygous familial nonfamilial ) Fredrickson type IIa IIb . history statinassociated myalgia , define unable tolerate two previous statin due muscle pain , ache , weakness , cramp begin increase statin therapy stop statin therapy discontinue . History statinassociated myalgia capture historical questionnaire statinassociated myalgia . LDLC &gt; 110 mg/dL triglyceride &lt; 500 mg/dL Prescreening . prescreening hemoglobin value ≥10 g/dL female ≥12 g/dL . patient agree stop antihyperlipidemic agent ( include limit niacin , probucol , ezetimibe , fibrates derivative , bile acidsequestering agent , 3hydroxy3methylglutarylcoenzyme A ( HMGCoA ) reductase inhibitor , fish oil , flaxseed oil , red yeast rice ) . patient agree stop Coenzyme Q10 supplement . take nonexcluded medication , patient must stable dose 4 week screen . history chronic pain currently experience chronic pain unrelated statin require chronic use pain medication , diagnose fibromyalgia severe neuropathic pain . require chronic use pain medication , include acetaminophen , nonsteroidal antiinflammatory medication , narcotic , analgesic . vitamin D insufficiency ( current insufficiency define Vitamin D3 &lt; 20 ng/mL [ 50 nmol/L ] measure Prescreening . hypothyroidism abnormal thyroid function test confirm thyroidstimulating hormone ≥ 5 mcIU/mL free thyroxine ( T4 ) &lt; 0.7 ng/dL Prescreening history rhabdomyolysis ( defined evidence organ damage creatinine kinase ( CK ) &gt; 10,000 IU/L ) . history liver disease history significant renal dysfunction define serum creatinine clearance &lt; 30 mL/min Nephroticrange proteinuria . HbA1C &gt; 9 % Prescreening . CK level &gt; 5 time upper limit normal Prescreening . congestive heart failure , even current therapy myocardial infarction , cardiac intervention , cerebrovascular accident/stroke transient ischemic attack le 6 month prior prescreening . patient pregnant ( confirmed laboratory test ) breastfeeding . history cancer ( basal cell and/or squamous cell carcinoma skin and/or Stage I squamous cell carcinoma cervix ) full remission least 1 year Screening . patient positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody , human immunodeficiency virus type 1 2 Prescreening .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Metabolic disease</keyword>
	<keyword>Lipid metabolism disorder</keyword>
	<keyword>Hyperlipoproteinemia Type IIa</keyword>
	<keyword>Hyperlipoproteinemia Type IIb</keyword>
	<keyword>Hypercholesterolemia , Autosomal Dominant</keyword>
	<keyword>Hypercholesterolemia , Autosomal Dominant , Type B</keyword>
	<keyword>Frederickson Type IIa</keyword>
	<keyword>Frederickson Type IIb Hyperlipidemia</keyword>
</DOC>